NASDAQ: ABOSAcumen Pharmaceuticals Inc Stock
$4.08+0.20 (+5.15%)
Updated Mar 22, 2023
ABOS Price
$4.08
Fair Value Price
N/A
Market Cap
$166.98M
52 Week Low
$3.02
52 Week High
$10.97
P/E
3.29x
P/B
0.85x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$38.34M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.03
Operating Cash Flow
-$28M
Beta
1.25
Next Earnings
Mar 27, 2023
Ex-Dividend
N/A
Next Dividend
N/A
ABOS Overview
Acumen Pharmaceuticals Inc. develops therapies for the treatment of Alzheimer's disease. Acumen's approach targets AbOs, a toxic and pathogenic form of Ab relative to Ab monomers and amyloid plaques. The company's lead immunotherapy drug candidate ACU193, is a humanized monoclonal antibody that is in Phase I clinical-stage trials. Acumen Pharmaceuticals was incorporated in 1996 and is headquartered in Charlottesville, VA.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ABOS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ABOS is good value based on its earnings relative to its share price (3.29x), compared to the US market average (22.44x)
P/E vs Market Valuation
ABOS is good value based on its earnings relative to its share price (3.29x), compared to the US Biotechnology industry average (16.9x)
P/E vs Industry Valuation
ABOS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more ABOS due diligence checks available for Premium users.
Be the first to know about important ABOS news, forecast changes, insider trades & much more!
ABOS News
Valuation
ABOS fair value
Fair Value of ABOS stock based on Discounted Cash Flow (DCF)
Price
$4.08
Fair Value
$9.41
Undervalued by
56.64%
ABOS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
3.29x
Industry
16.9x
Market
22.44x
ABOS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ABOS is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
ABOS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.85x
Industry
4.76x
ABOS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ABOS's financial health
Profit margin
Revenue
$0.0
Net Income
-$10.7M
Profit Margin
0%
ABOS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$203.3M
Liabilities
$6.6M
Debt to equity
0.03
ABOS's short-term assets ($202.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABOS's short-term assets ($202.56M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABOS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.2M
Investing
$55.9M
Financing
-$263.0k
ABOS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ABOS vs Biotech Stocks
Acumen Pharmaceuticals Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.